Almac Group’s Asia Pacific Headquarters Receives Official Health Science Authority (HSA) Accreditation

September 7, 2015

Singapore, 7 September 2015

Following on the recent announcement; ‘Almac Group Expands Asia Pacific Presence with New Regional Headquarters and Clinical Trial Supply Facility in Singapore’ (10 July 2015) detailing the successful completion of the Health Sciences Authority (HSA) inspection of their new Asia Pacific headquarters in Singapore, Almac can now officially confirm that, as a result of this inspection, the facility has received full GMP accreditation.

“We’re delighted to obtain the Health Sciences Authority’s certification of our Singapore facility,” commented Paul O’Connor, Global VP of Quality for Almac Group. “This development makes Almac the first full service clinical trial packaging and distribution organization to ever receive GMP accreditation and solidifies Almac’s commitment to provide the highest possible standard of service to our customers in Asia Pacific and indeed around the world.”

About Almac Group  

‘Partnering to Advance Human Health’

The Almac Group is an established contract development and manufacturing organization that provides an extensive range of integrated services to the pharmaceutical and biotech sectors globally. The services range from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.

The international company is a privately owned organization that has organically grown over 30 years and now employs in excess of 3,700 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with operations in the UK, across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Tokyo).

For more information, please contact:

Ruder Finn Asia

Ayuni Ali

Senior Account Executive

D: +65 6336 8750

E: [email protected]


Prasanthi Nair

Account Executive

D: +65 6336 6742

E: [email protected]


Back to news